专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP1490480B1 PRIMITIVE AND PROXIMAL HEPATIC STEM CELLS 失效转让
标题翻译：主席UNDITEXIMALE LEBERSTAMMZELLEN
公开(公告)号：EP1490480B1
公开(公告)日：2016-02-03
申请号：EP03728245.6
申请日：2003-03-14
申请人： University of North Carolina at Chapel Hill , Incara Cell Technologies, Inc.
发明人： REID, Lola , MOSS, Nicholas, G. , FURTH, Mark, E. , LUDLOW, John, W. , BRUCE, Andrew, T.
IPC分类号： C12N5/071 , C12N5/074 , A61K35/413
CPC分类号： C12N5/0672 , C12N2500/25 , C12N2500/36 , C12N2500/90 , C12N2501/11 , C12N2502/13 , G01N33/5005 , G01N33/68 , G01N2333/705 , G01N2333/70525 , G01N2333/70596
摘要： Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor. Proximal hepatic stem cells may also be isolated by culturing colonies comprising a primitive hepatic stem cell under conditions which include a developmental factor. Resulting compositions may be used for treating liver disorders and for producing bioartificial organs.
摘要翻译：肝祖细胞包含两个人类肝干细胞，原始和近端肝干细胞，以及两个定型祖细胞群，一个为胆汁细胞，一个为肝细胞。人原始肝干细胞是肝细胞群体的一小部分，并且产生近肝组织肝脏部分的肝干细胞。人近端肝干细胞产生胆汁和肝细胞定向的祖细胞。原始和近端干细胞是人类肝脏的主要干细胞。人原始肝干细胞可以通过人肝脏的免疫选择或在选择人原始肝干细胞的条件下培养人肝细胞来分离。可以通过免疫选择或通过在包括发育因子的条件下培养人肝细胞来分离近端肝干细胞。也可以通过在包括发育因子的条件下培养包含原始肝干细胞的菌落来分离近端肝干细胞。所得组合物可用于治疗肝脏疾病和用于生产生物人造器官。

2. 发明公开

EP1863520A4 USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER 有权
标题翻译：白细胞介素17E对癌症治疗中的应用
公开(公告)号：EP1863520A4
公开(公告)日：2009-10-21
申请号：EP06705265
申请日：2006-03-08
申请人： LORUS THERAPEUTICS INC
发明人： WRIGHT JIM A , YOUNG AIPING H , LEE YOON , CAO MING YU
IPC分类号： A61K38/20 , A61K31/337 , A61K31/4164 , A61K31/7088 , A61K35/413 , A61K39/395 , A61P35/00
CPC分类号： A61K38/20 , A61K31/337 , A61K31/4164 , A61K31/7088 , A61K2039/505 , A61K2300/00 , C07K16/22 , C07K2317/24 , C07K2317/76
摘要： The use of interleukin 17E to inhibit tumor growth in a subject is provided. The interleukin 17E can be provided to the subject exogenously, as an interleukin 17E polypeptide or a polynucleotide encoding an interleukin 17E polypeptide, or it can be provided by stimulating production of endogenous interleukin 17E. Also provided is the use of interleukin 17E in combination with one or more anti-cancer therapeutics for inhibiting tumor growth in a subject. Anti-cancer therapeutics include, for example, standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation and antisense therapy.

3. 发明公开

EP1863520A1 USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER 有权
标题翻译：白细胞介素17E对癌症治疗中的应用
公开(公告)号：EP1863520A1
公开(公告)日：2007-12-12
申请号：EP06705265.4
申请日：2006-03-08
申请人： Lorus Therapeutics Inc.
发明人： WRIGHT, Jim, A. , YOUNG, Aiping, H. , LEE, Yoon , CAO, Ming, Yu
IPC分类号： A61K38/20 , A61K31/4164 , A61K31/337 , A61K31/7088 , A61K35/413 , A61K39/395 , A61P35/00
CPC分类号： A61K38/20 , A61K31/337 , A61K31/4164 , A61K31/7088 , A61K2039/505 , A61K2300/00 , C07K16/22 , C07K2317/24 , C07K2317/76
摘要： The use of interleukin 17E to inhibit tumor growth in a subject is provided. The interleukin 17E can be provided to the subject exogenously, as an interleukin 17E polypeptide or a polynucleotide encoding an interleukin 17E polypeptide, or it can be provided by stimulating production of endogenous interleukin 17E. Also provided is the use of interleukin 17E in combination with one or more anti-cancer therapeutics for inhibiting tumor growth in a subject. Anti-cancer therapeutics include, for example, standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation and antisense therapy.

4. 发明授权

EP1863520B1 USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER 有权
标题翻译：白细胞介素17E对癌症治疗中的应用
公开(公告)号：EP1863520B1
公开(公告)日：2014-12-31
申请号：EP06705265.4
申请日：2006-03-08
申请人： Aptose Biosciences Inc.
发明人： WRIGHT, Jim, A. , YOUNG, Aiping, H. , LEE, Yoon , CAO, Ming, Yu
IPC分类号： A61K38/20 , A61K31/4164 , A61K31/337 , A61K31/7088 , A61K35/413 , A61K39/395 , A61P35/00
CPC分类号： A61K38/20 , A61K31/337 , A61K31/4164 , A61K31/7088 , A61K2039/505 , A61K2300/00 , C07K16/22 , C07K2317/24 , C07K2317/76
摘要： The use of interleukin 17E to inhibit tumor growth in a subject is provided. The interleukin 17E can be provided to the subject exogenously, as an interleukin 17E polypeptide or a polynucleotide encoding an interleukin 17E polypeptide, or it can be provided by stimulating production of endogenous interleukin 17E. Also provided is the use of interleukin 17E in combination with one or more anti-cancer therapeutics for inhibiting tumor growth in a subject. Anti-cancer therapeutics include, for example, standard chemotherapeutic drugs, immunotherapeutics, radiation, gene therapy, hormone manipulation and antisense therapy.

5. 发明公开

EP1333847A1 COMBINATION PREPARATION OF A BIOLOGICAL RESPONSE MODIDIER AND AN ANTICANCER AGENT AND USES THEREOF 审中-公开
标题翻译：复方制剂ENTHLTEND生物学行为变化的物质和抗癌制剂及其用途
公开(公告)号：EP1333847A1
公开(公告)日：2003-08-13
申请号：EP01983364.9
申请日：2001-11-08
申请人： Lorus Therapeutics Inc.
发明人： YOUNG, Aiping, H.
IPC分类号： A61K35/413 , A61P35/00
CPC分类号： A61K35/413 , A61K38/20 , A61K38/21 , A61K45/06 , A61K2300/00
摘要： The present invention provides anticancer biological response modifier combinations. In accordance with an aspect of the present invention, there is provided a combination comprising: (i) a composition comprising small molecular weight components of less than 3000 daltons, and having the following properties: is extracted from bile of animals; is capable of stimulating monocytes and/or macrophages in vitro and/or in vivo; is capable of modulating tumor necrosis factor production and/or release; contains no measurable level of IL-1α, IL-1β, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-gamma; is not cytotoxic to human peripheral blood mononuclear cells; is not an endotoxin; and (ii) one or more anticancer agent(s), wherein said combination has therapeutic synergy or improves the therapeutic index in the treatment of cancer over the composition or the anticancer agent(s) alone. Another aspect of the present invention provides the use of this combination in the manufacture of a medicament or a pharmaceutical kit and in the treatment of cancer.

6. 发明公开

EP0919238A3 Crude drug extract containing soluble silicon 审中-公开
标题翻译： Ein Roharzneimittel Extrakt enthaltendelöslissSilizium
公开(公告)号：EP0919238A3
公开(公告)日：1999-10-27
申请号：EP98122198.9
申请日：1998-11-27
申请人： NIPPON ZOKI PHARMACEUTICAL CO., LTD.
发明人： Konishi, Jin-emon
IPC分类号： A61K35/12 , A61K35/413 , A61K35/78 , A61K35/84 , G01N33/52
CPC分类号： G01N33/52 , A61K36/00 , A61K36/07 , A61K2300/00
摘要： [Object of the Invention] The present invention is to offer a crude drug extract containing soluble silicon compounds as an effective component and also to offer a standardization method therefor. [Means for Achieving That] The crude drug extract of the present invention can be prepared by extraction of various crude drugs derived from animals, plants, etc. and quality of the crude drug extract can be standardized using the soluble silicon compounds as an index. [Merit] As such, in accordance with the present invention, soluble silicon compounds related to the pharmaceutical effect is used as an index whereby quality of various crude drugs can be standardized which contributes to offer crude drug extracts having a stable quality. Consequently, the present invention greatly contributes to the appropriate standardization of pharmaceuticals.
摘要翻译：本发明提供含有可溶性硅化合物的生物药物提取物作为有效成分，并提供其标准化方法。 Ä实现方法本发明的生药提取物可以通过提取源自动物，植物等的各种生药来制备，并且可以使用可溶性硅化合物作为指标来标准化生物药物提取物的质量。 ÄMeritÜ因此，根据本发明，使用与药效有关的可溶性硅化合物作为指标，其中可以标准化各种生药的质量，这有助于提供具有稳定质量的生药提取物。因此，本发明大大有助于药物的适当标准化。

7. 发明公开

EP0383964A1 Dietary fat reduction 失效
标题翻译： Verminderung der Nahrungsfettaufnahme。
公开(公告)号：EP0383964A1
公开(公告)日：1990-08-29
申请号：EP89102954.8
申请日：1989-02-21
申请人： SEE/SHELL BIOTECHNOLOGY, INC.
发明人： Shell, William E. , See, Jackie R.
IPC分类号： A61K9/16 , A61K31/575 , A61K35/413 , A23L1/303
CPC分类号： A61K31/575 , A61K9/167 , A61K35/413 , Y10S514/909 , Y10S514/951 , Y10T428/2989
摘要： A method and a composition for accumulating and the binding of food fats in an animal body gastrointestinal tract. The method and composition rely upon non-biodegradable particles, such as microspheres, having a size of at least two microns and a fat receptor, such as bile, capable of having food fat adhered thereto on the surface of the particles. These particles are sufficiently large so that they do not pass through the surface mucosa of the gastrointestinal tract and permit the particles with the food fat to pass through the gastrointestinal tract and out of the body through animal excretion.
摘要翻译：用于在动物体胃肠道中积聚和结合食物脂肪的方法和组合物。该方法和组合物依赖于能够在颗粒表面附着食物脂肪的不可生物降解的颗粒，例如具有至少两微米尺寸的微球，以及脂肪受体（例如胆汁）。这些颗粒足够大，使得它们不通过胃肠道的表面粘膜，并允许具有食物脂肪的颗粒通过动物排泄通过胃肠道并从体外通过。

8. 发明公开

EP3597201A2 COMBINATION THERAPY FOR TREATMENT OF PATIENTS WITH NEUROLOGICAL DISORDERS AND CEREBRAL INFARCTION 审中-公开
公开(公告)号：EP3597201A2
公开(公告)日：2020-01-22
申请号：EP19196391.7
申请日：2009-11-10
申请人： Moleac Pte Ltd.
发明人： PICARD, David , SHI, Xue Min , LAZDUNSKI, Michel
IPC分类号： A61K35/36 , A61K35/413 , A61K35/62 , A61K35/63 , A61K35/646 , A61K36/232 , A61K36/481 , A61K36/537 , A61K36/65 , A61K36/69 , A61K36/88 , A61K38/00 , A61K45/06
摘要： The present invention provides compositions and methods for treating stroke patients using traditional Chinese medicine, such as NeuroAid. The composition comprising at least one of the following Honghua, Taoren, DanGui, Deer Horn, in combination with at least one of the following: Radix Astragali root (Membranous Milkvetch root or Huang Qi), Radix et Rhizoma Salviae Miltiorrhizae root (Red Sage root or Dan Shen), Radix Paeoniae Rubra root (Red Peony root or Chi Shao), rhizome of Ligusticum Chuanxiong (Chuan Xiong), Radix et Rhizoma Notoginseng (Sanqi) Cortex moutan (Peony or Mudanpi), Wood of Odoriferous Rosewood (Jiang Xiang), dried body of Scorpion (Quan Xie), Radix Polygalae root (Yuan Zhi), Grassleaf sweetflag rhizome (Shi Changpu), Leeches (Hirudo or Shuizhi), Ground Beetle (or Tu Bie Chong), Natural or Artificial Cow-bezoar (calculus Bovis artifactus or Rengong Niuhuang), Gambirplant stem With hooks (Ramulus uncariae cum uncis or Gou Teng) and a Western medicament used for the treatment of stroke patients.

9. 发明公开

EP2845599A1 CHINESE HERBAL COMPOUND ANTI-TUMOUR NANOPREPARATION AND USE THEREOF 有权
标题翻译：中草药复方抗肿瘤纳米复合材料及其应用
公开(公告)号：EP2845599A1
公开(公告)日：2015-03-11
申请号：EP14780742.4
申请日：2014-02-13
申请人： Shanghai University of Traditional Chinese Medicine
发明人： FENG, Nianping , SHI, Feng , LIU, Ying , ZHAO, Jihui , ZHANG, Yongtai
IPC分类号： A61K36/328 , A61K36/324 , A61K33/36 , A61K35/413 , A61K35/55 , A61P35/00
CPC分类号： A61K36/328 , A61K9/5123 , A61K9/5192 , A61K33/36 , A61K35/36 , A61K35/55 , A61K36/324 , A61K2300/00
摘要： A traditional Chinese medicine compound antitumor nano preparation, comprising the following components by weight percentage: 28%-32% of solid lipid nanoparticles containing volatile oil of frankincense and myrrh, 61%-65% of nano realgar carrying microcapsule, 0.8%-1.3% of bezoar micro-powder and 4%-6% of musk micro-powder. Use of the above traditional Chinese medicine compound antitumor nano preparation for preparing antitumor drugs. The traditional Chinese medicine compound antitumor nano preparation of the present invention can remarkably improve bioavailability of every component in the traditional Chinese medicine compound; at the same time, it can achieve better curative effect with reduced dosage.
摘要翻译：一种中药复方抗肿瘤纳米制剂，包括以下重量百分比的组分：含乳香和没药挥发油的固体脂质纳米粒子28％-32％，载纳纳米雄黄微囊的61％-65％，含有0.8％-1.3％的牛黄微粉和4％-6％的麝香微粉。上述中药复方抗肿瘤纳米制剂用于制备抗肿瘤药物的用途。本发明的中药复方抗肿瘤纳米制剂可显着提高中药复方中各组分的生物利用度，同时减少用量可以达到更好的疗效。

10. 发明公开

EP1940428A4 BILE PREPARATIONS FOR GASTROINTESTINAL DISORDERS 审中-公开
标题翻译： GALLEN筹备胃肠疾病
公开(公告)号：EP1940428A4
公开(公告)日：2012-05-02
申请号：EP06738034
申请日：2006-03-10
申请人： YOO SEO HONG
发明人： YOO SEO HONG
IPC分类号： A61K35/413 , A61K9/08 , A61K45/06 , A61K47/28 , A61K47/36 , A61K47/48 , A61P1/00
CPC分类号： A61K9/0095 , A61K31/575 , A61K31/715 , A61K31/718 , A61K35/413 , A61K45/06 , A61K47/554 , A61K2300/00
摘要： The present disclosure is related to clear aqueous solutions of one or more bile acids and either an aqueous soluble starch conversion product or a non-starch polysaccharide. Solutions of the disclosure may be administered to a subject in conjunction with a pharmaceutical compound having one or more toxic effects. In some embodiments, solutions of the disclosure are administered to a mammal in conjunction with a pharmaceutical compound associated with a peripherial neurotoxicity (e.g., cisplatin and/or suramin) to reduce or eliminate the neuropathic effect(s).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式